Regents Of The University Of California Allogene Therapeutics, Inc. Transaction History

Regents Of The University Of California

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 27, 2021	SELL	$23.49 - $35.8 $15.9 Million - $24.2 Million	-675,743 Closed	0 $0
Q1 2021 Apr 20, 2021	SELL	$25.79 - $39.02 $5.79 Million - $8.76 Million	-224,400 Reduced 24.93%	675,743 $23.9 Million
Q4 2020 Jan 21, 2021	BUY	$25.24 - $43.45 $22.7 Million - $39.1 Million	900,143 New	900,143 $22.7 Million
Q3 2020 Oct 21, 2020	SELL	$32.38 - $44.96 $41.4 Million - $57.5 Million	-1,279,281 Closed	0 $0
Q2 2020 Jul 23, 2020	SELL	$18.39 - $54.04 $19.7 Million - $57.9 Million	-1,071,649 Reduced 45.58%	1,279,281 $54.8 Million
Q4 2019 Feb 10, 2020	BUY	$24.82 - $31.4 $58.4 Million - $73.8 Million	2,350,930 New	2,350,930 $61.1 Million

173

132M

94.3K

112K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $431M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Regents Of The University Of California, based on Form 13F filings with the SEC.

Stay updated on Regents Of The University Of California with notifications on news.